Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment.
Rafael Morales-BarreraGuillermo VillacampaNatalia VidalMariona FigolsJulia GinerTeresa BonfillCristina SuárezNely DíazJoaquín MateoMacarena GonzálezMontserrat DomenechJavier PuenteJoan CarlesPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2023)
Our findings suggest that development of irAEs was associated with higher ORR, and patients who developed grade 1-2 irAEs had longer OS. Prospective studies are necessary to confirm our findings.